ATIM-12. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH BEVACIZUMAB (BEV)-REFRACTORY RECURRENT GLIOBLASTOMA (GBM)

BACKGROUND: GBM patients who progress on BEV, an approved angiogenesis inhibitor for recurrent GBM, have a dismal outcome with a median survival of < 6 months. DUR is a human IgG1 monoclonal Ab against PD-L1. METHODS: This ongoing Phase 2 open-label study (NCT02336165) evaluates safety and effica...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Reardon, David, Kaley, Thomas, Dietrich, Jorg, Clarke, Jennifer L, Dunn, Gavin P, Lim, Michael, Cloughesy, Timothy, Gan, Hui K, Park, Andrew, Schwarzenberger, Paul, Ricciardi, Toni, Macri, Mary, Ryan, Aileen, Venhaus, Ralph
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2017
Konular:
Abstracts
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692026/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.108
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller